SCHEMBL1932071

SCHEMBL1932071

CN(C)c1ccc(N)cc1-c1ccc(O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP7 Q93009 3/20 0.43
THRB P10828 2/20 0.41
ALDH1A1 P00352 1/20 0.41
CA3 P07451 1/20 0.41
CYP3A4 P08684 1/20 0.41
ALOX15 P16050 1/20 0.41
CA6 P23280 1/20 0.41
CASP1 P29466 1/20 0.41
HIF1A Q16665 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CA14 Q9ULX7 1/20 0.41
FYN P06241 1/20 0.40
CLK1 P49759 1/20 0.39
DYRK1A Q13627 1/20 0.39
DYRK2 Q92630 1/20 0.39
DYRK1B Q9Y463 1/20 0.39
APP P05067 2/20 0.39
PDE10A Q9Y233 1/20 0.38
MAPT P10636 2/20 0.37
TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3784069 0.89 ALDH1A1 (0.43) ALDH1A1CYP3A4ALOX15HSD17B10DYRK1A
SCHEMBL21629684 0.84 ALDH1A1 (0.54) ALDH1A1CYP3A4ALOX15HSD17B10MAPT
SCHEMBL3786195 0.81 PGR (0.43) ALDH1A1CYP3A4HSD17B10DYRK1AMAPT
SCHEMBL10956325 0.80 ALDH1A1 (0.44) ALDH1A1CYP3A4ALOX15CASP1DYRK1A
Hydrochloric Acid SCHEMBL6572274 0.80 PGR (0.42) ALDH1A1CYP3A4HSD17B10DYRK1ATP53
SCHEMBL27962615 0.79 CASP1 (0.52) USP7THRBALDH1A1CA3CYP3A4
SCHEMBL11879823 0.79 ESR2 (0.43) USP7THRBALDH1A1CA3CYP3A4
SCHEMBL6571486 0.78 USP7 (0.40) USP7THRBALDH1A1CA3CYP3A4
SCHEMBL3786869 0.76 MAOA (0.45) ALDH1A1CYP3A4CASP1MAPT
SCHEMBL6572455 0.76 USP7 (0.35) USP7THRBALDH1A1CA3CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8609652-B2 Method of administering a methylene blue-curcumin analog for the treatment of alzheimer's disease DePuy Synthes Products, LLC (US) 2013-12-17 US disclosed
US-20110130392-A1 Method of Administering a Methylene Blue - Curcumin Analog for the Treatment of Alzheimer's Disease DEPUY SPINE, LLC 2011-06-02 US disclosed
US-7906643-B2 Methylene blue-curcumin analog for the treatment of Alzheimer's Disease CODMAN & SHURTLEFF, INC. (US) 2011-03-15 US disclosed
US-20100190978-A1 METHYLENE BLUE - CURCUMIN ANALOG FOR THE TREATMENT OF ALZHEIMER'S DISEASE CODMAN & SHURTLEFF, INC. 2010-07-29 US disclosed
WO-2010085739-A1 METHYLENE BLUE - CURCUMIN ANALOG FOR THE TREATMENT OF ALZHEIMER'S DISEASE CODMAN & SHURTLEFF, INC. (US) 2010-07-29 WO disclosed
US-7723515-B1 Methylene blue—curcumin analog for the treatment of alzheimer's disease CODMAN & SHURTLEFF, INC. (US) 2010-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190978-A1 METHYLENE BLUE - CURCUMIN ANALOG FOR THE TREATMENT OF ALZHEIMER'S DISEASE APP, PSEN2, MAPT USP7 670/4885THRB 2018/4885ALDH1A1 441/4885
US-20110130392-A1 Method of Administering a Methylene Blue - Curcumin Analog for the Treatment of Alzheimer's Disease APP, PSEN2, MAPT USP7 421/4885THRB 2233/4885ALDH1A1 438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.